Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.50 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | GLP1R | P43220 | 8/20 | 0.46 |
| ▸ | ALB | P02768 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20910956 | 1.00 | EPHX2 (0.50) | EPHX2PRMT1FOLH1NOD1ADRA1A | |
| SCHEMBL20911129 | 0.92 | GLP1R (0.56) | EPHX2FOLH1NOD1GLP1R | |
| SCHEMBL20911434 | 0.92 | GLP1R (0.56) | EPHX2FOLH1NOD1GLP1R | |
| SCHEMBL20900403 | 0.88 | EPHX2 (0.51) | EPHX2PRMT1FOLH1NOD1ADRA1A | |
| SCHEMBL20900398 | 0.88 | EPHX2 (0.51) | EPHX2PRMT1FOLH1NOD1ADRA1A | |
| SCHEMBL21110473 | 0.88 | EPHX2 (0.48) | EPHX2PRMT1FOLH1NOD1ADRA1A | |
| SCHEMBL12673978 | 0.88 | EPHX2 (0.48) | EPHX2PRMT1FOLH1NOD1ADRA1A | |
| SCHEMBL21110624 | 0.88 | EPHX2 (0.48) | EPHX2PRMT1FOLH1NOD1ADRA1A | |
| SCHEMBL20911567 | 0.88 | EPHX2 (0.48) | EPHX2PRMT1FOLH1NOD1ADRA1A | |
| SCHEMBL14412579 | 0.88 | GNPAT (0.55) | EPHX2PRMT1FOLH1NOD1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190112348-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2019-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112348-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | EPHX2 4491/4885PRMT1 3732/4885FOLH1 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.